Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.
For the
three
months ended in Mar. 2026,
Inovio Pharmaceuticals receivedMXN19.55 Mil more from issuing new shares than it paid to buy back shares.
It receivedMXN0.00 Mil from issuing more debt.
It paidMXN0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.
It receivedMXN0.00 Mil from paying cash dividends to shareholders.
It spentMXN2.34 Mil on other financial activities.
In all, Inovio PharmaceuticalsearnedMXN17.20 Mil on financial activities for the
three
months ended in Mar. 2026.
Inovio Pharmaceuticals (MEX:INO) Cash Flow from Financing Explanation
Cash from financing contains six items:
1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.
Inovio Pharmaceuticals's issuance of stock for the
three
months ended in Mar. 2026 was MXN19.55 Mil.
2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.
Inovio Pharmaceuticals's repurchase of stock for the
three
months ended in Mar. 2026 was MXN0.00 Mil.
3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.
Inovio Pharmaceuticals's net issuance of debt for the
three
months ended in Mar. 2026 was MXN0.00 Mil.
Inovio Pharmaceuticals receivedMXN0.00 Mil from issuing more debt.
4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.
Inovio Pharmaceuticals's net issuance of preferred for the
three
months ended in Mar. 2026 was MXN0.00 Mil.
Inovio Pharmaceuticals paidMXN0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.
5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.
Inovio Pharmaceuticals's cash flow for dividends for the
three
months ended in Mar. 2026 was MXN0.00 Mil.
Inovio Pharmaceuticals receivedMXN0.00 Mil from paying cash dividends to shareholders.
6. Other Financing:
Money spent or earned by company from other financial activities.
Inovio Pharmaceuticals's other financing for the
three
months ended in Mar. 2026 was MXN-2.34 Mil.
Inovio Pharmaceuticals spentMXN2.34 Mil on other financial activities.
Inovio Pharmaceuticals Cash Flow from Financing Related Terms
Inovio Pharmaceuticals Cash Flow from Financing Historical Data
* Premium members only.
The historical data trend for Inovio Pharmaceuticals's Cash Flow from Financing can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inovio Pharmaceuticals Cash Flow from Financing Chart
Inovio Pharmaceuticals Cash Flow from Financing Calculation
This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.
Inovio Pharmaceuticals's Cash from Financing for the fiscal year that ended in Dec. 2025 is calculated as:
Cash Flow from Financing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN962.30 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash Flow from Financing of MXN962.30 Mil mean?
Inovio Pharmaceuticals (MEX:INO) has a Cash Flow from Financing of MXN962.30 Mil as of Mar. 2026. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Inovio Pharmaceuticals and its competitors.
Is Inovio Pharmaceuticals' Cash Flow from Financing too high?
Inovio Pharmaceuticals' current Cash Flow from Financing is MXN962.30 Mil. Overall, Inovio Pharmaceuticals has a GF Score™ of 40/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Inovio Pharmaceuticals' Cash Flow from Financing compare to TELO and ELTX?
Inovio Pharmaceuticals' Cash Flow from Financing of MXN962.30 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Financing for a Biotechnology company?
A good Cash Flow from Financing depends on the Biotechnology industry context. However, Cash Flow from Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Financing mean?
A high Cash Flow from Financing can signal that a stock is expensive relative to its fundamentals. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for Inovio Pharmaceuticals and its competitors. Inovio Pharmaceuticals's current Cash Flow from Financing is MXN962.30 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inovio Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Inovio Pharmaceuticals (MEX:INO) is currently considered Significantly Overvalued. The stock's GF Value™ is MXN3.68, compared to a current price of MXN11.50 — trading 212.5% above its estimated fair value. The current Cash Flow from Financing is MXN962.30 Mil. Inovio Pharmaceuticals' overall GF Score™ is 40/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Financing calculated?
Cash Flow from Financing is calculated from a company's financial statements. For Inovio Pharmaceuticals (MEX:INO), the current Cash Flow from Financing is MXN962.30 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Inovio Pharmaceuticals (MEX:INO) Overvalued in 2026?
Based on GuruFocus' analysis, Inovio Pharmaceuticals stock appears to be overvalued.
The current stock price of MXN11.50 is trading 212.5% above its estimated GF Value™ of MXN3.68.
GuruFocus considers Inovio Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for MEX:INO:
Cash Flow from Financing: MXN962.30 Mil
GF Value™: MXN3.68 vs. price of MXN11.50 (212.5% above fair value)
No single metric tells the full story. See the MEX:INO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP.
40GF Score
Get the complete analysis for MEX:INO
Cash Flow from Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:INO has been successfully added to your 
